Haisco Pharmaceutical Group Co., Ltd.
Quick facts
Marketed products
Phase 3 pipeline
- Acetyllevocarnitine Hydrochloride Tablets · Neurology / Metabolic disorders
Acetyl-L-carnitine enhances cellular energy production by facilitating the transport of long-chain fatty acids into mitochondria for beta-oxidation. - HL231 Solution for Inhalation
HL231 is an inhaled formulation designed to deliver therapeutic agents directly to the respiratory tract for local and/or systemic effects. - HSK31858, tablet · Oncology
HSK31858 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HSK39297 · Oncology
HSK39297 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HSK39297 tablets
HSK39297 is an investigational small molecule that modulates specific cellular pathways to treat its target indication.
Phase 2 pipeline
- HSK16149
- HSK21542 dose level 1
- HSK21542 dose level 2
- HSK31679 high dose
- HSK31679 low dose
- HSK31679 medium dose
- HSK31858
- HSK36273
- HSK39004
- HSK39004 Dry Powder Inhaler Simulant
- HSK39004 inhalation suspension
- HSK39297 100mgBID
- HSK39297 200mgQD
- HSK39297 300mgQD
- HSK39297 50mgBID
- HSK44459 dose level 1
- HSK44459 dose level 2
- HSK44459 tablets
- HSK47388
Phase 1 pipeline
- [14C]HSK21542
- Carbon-14 labeled HSK39297
- HSK16149，probenecid, cimetidine
- HSK29116
- HSK31679
- HSK31858 Tablets and Itraconazole Capsules
- HSK39004 in COPD
- HSK39004 in healthy
- HSK40118
- HSK41959
- HSK42360
- HSK46575
- HSK47977
- HSK7653
- HSK7653 tablets
- Mefanamic Acid
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: